Holen Sie sich die Stockscreener-App
0.0539
6.52%
0.0033
Vorhandelsmarkt:
.05
-0.0039
-7.24%
Schlusskurs vom Vortag:
$0.0506
Offen:
$0.05
24-Stunden-Volumen:
5.94M
Relative Volume:
0.98
Marktkapitalisierung:
$3.30M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-28.80%
1M Leistung:
-50.09%
6M Leistung:
-93.80%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.0481
$0.055
1-Wochen-Bereich:
$0.0481
$0.075
52-Wochen-Spanne:
$0.0481
$4.31
Psyence Biomedical Ltd Stock (PBM) Company Profile
Firmenname
Psyence Biomedical Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie PBM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| PBM | 0.0539 | 3.30M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Psyence Biomedical Ltd Aktie (PBM) Neueste Nachrichten
Psyence Biomedical fell on 75-to-1 share consolidation and Nasdaq delisting notice - MSN
Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq - The Manila Times
Psyence Biomedical Shareholders Approve 75:1 Stock Split Amid Nasdaq Compliance Challenge | PBM Stock News - StockTitan
Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs - GlobeNewswire
Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs - Yahoo Finance
Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group's Stake in PsyLabs - The Manila Times
Where Do Analysts See Psyence Biomedical Ltd. (NASDAQ: PBM) Heading? - Stocks Register
Bullish Prospects For Psyence Biomedical Ltd. (NASDAQ: PBM) Shares In 2024 - Stocks Register
Natural Gas LDay (F) (HHM19) Quote - The Globe and Mail
Psyence Biomed adds Australian site for psilocybin trial - Investing.com
Psyence Biomed adds Australian site for psilocybin trial By Investing.com - Investing.com South Africa
Psyence Biomed Announces Recruitment of Second Clinical - GlobeNewswire
Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care - StockTitan
Psyence Biomedical Sets Annual General Meeting for November 12 - Investing.com
Psyence Biomedical Plans Key Shareholder Meeting - TipRanks
Psyence Biomedical Sets Annual General Meeting for November 12 By Investing.com - Investing.com UK
Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development - The Manila Times
Psyence Biomedical Ltd. (PBM) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
How analysts predict Psyence Biomedical Ltd. (PBM) will perform this quarter? - US Post News
Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical - The Manila Times
Gaining Ground: Psyence Biomedical Ltd. (PBM) Closes Higher at 0.10, Up 5.70 - The Dwinnex
What is Psyence Biomedical Ltd. (PBM) Stock Return on Shareholders’ Capital? - SETE News
Psyence Biomedical Ltd. [PBM] is -98.82% lower this YTD. Is it still time to buy? - The DBT News
Investor Alert: What’s Really Going On At Psyence Biomedical Ltd. (NASDAQ: PBM) - Stocks Register
There is no way Psyence Biomedical Ltd. (PBM) can keep these numbers up - SETE News
Psyence Biomedical Converts Debt to Equity - TipRanks
PBM’s Stock Journey: What Investors Need to Know About Psyence Biomedical Ltd.’s Performance - The InvestChronicle
Is it possible to buy Psyence Biomedical Ltd.(PBM) shares at a good price now? - US Post News
Financial Analysis: Psyence Biomedical Ltd. (PBM)’s Ratios Unveil Key Insights - The Dwinnex
PBMPsyence Biomedical Ltd. Common Shares Latest Stock News & Market Updates - StockTitan
Psyence Biomed halts Clairvoyant Therapeutics acquisition - Investing.com
Psyence Biomed halts Clairvoyant Therapeutics acquisition By Investing.com - Investing.com UK
Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant - The Manila Times
Views of Wall Street’s Leading Experts on Psyence Biomedical Ltd. - SETE News
Psyence Biomedical Ltd. (PBM) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Market Momentum: Psyence Biomedical Ltd. (PBM) Registers a -1.10 Decrease, Closing at 0.11 - The Dwinnex
Psyence Biomedical Ltd. (PBM) stock analysis: A comprehensive overview - US Post News
Psyence Biomedical Ltd. (PBM): Be Patient, You Will Learn - Stocks Register
An analyst sees good growth prospects for Psyence Biomedical Ltd. (PBM) - SETE News
Psyence Group offloads PsyLabs stake to spinoff - Green Market Report
A stock that deserves closer examination: Psyence Biomedical Ltd. (PBM) - US Post News
Stock Performance Spotlight: Psyence Biomedical Ltd. (PBM) Ends the Day at 0.12, Down by -6.11 - The Dwinnex
Psyence Group Sells Stake to Psyence Biomedical - TipRanks
Psyence Biomed acquires stake in PsyLabs for $1.1 million By Investing.com - Investing.com Canada
Psyence Biomed acquires stake in PsyLabs for $1.1 million - Investing.com
Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs - StockTitan
Psyence inks several deals to expand psilocybin research, footprint - Green Market Report
A new trading data show Psyence Biomedical Ltd. (PBM) is showing positive returns. - SETE News
Psyence Biomedical Ltd. (PBM) Stock: A Year of Declines and Increases - The InvestChronicle
Balance Sheet Insights: Psyence Biomedical Ltd. (PBM)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Psyence Biomedical Trials Psilocybin for Palliative Care - TipRanks
Finanzdaten der Psyence Biomedical Ltd-Aktie (PBM)
Es liegen keine Finanzdaten für Psyence Biomedical Ltd (PBM) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):